A comparison of bare-metal and drug-eluting stents for off-label indications

New England Journal of Medicine

Volumn 358, Issue 4, 2008, Pages 342-352

  Marroquin, Oscar C ^a,g   Selzer, Faith ^a   Mulukutla, Suresh R ^a   Williams, David O ^b   Vlachos, Helen A ^a   Wilensky, Robert L ^c   Tanguay, Jean François ^d   Holper, Elizabeth M ^e   Abbott, J Dawn ^b   Lee, Joon S ^a   Smith, Conrad ^a   Anderson, William D ^a   Kelsey, Sheryl F ^a   Kip, Kevin E ^f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; ARTERY DIAMETER; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; CORONARY STENT; DATA ANALYSIS; DIABETES MELLITUS; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LEFT CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; THERAPY EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT RESPONSE; AGED; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; HEART INFARCTION; MIDDLE AGED; MORTALITY; OBSERVATION; PACKAGING; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS; STENT; SURVIVAL;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; OBSERVATION; PRODUCT LABELING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STENTS; SURVIVAL ANALYSIS;

EID: 38549120402     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0706258     Document Type: Article

References (19)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
2. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
3. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
4. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
5. Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
6. Schampaert E, Cohen EA, Schlüter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
7. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
8. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13.
9. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23.
10. Weisz G, Leon MB, Holmes DR Jr, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006;47:1350-5.
11. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
12. Lagerqvist B, James SK, Stenestrand S, Lindbäck J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
13. Mauri L, Hsieh W, Massaro JM, Ho K, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
14. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N Engl J Med 2007;356:984-7.
15. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 2000;102:2945-51.
16. CYPHER sirolimus-eluting stent: essential prescribing information. Miami: Cordis. (Available at http://www.cordis.com.)
17. TAXUS Express stent system: directions for use. Natick, MA: Boston Scientific. (Available at http://www.taxus-stent.com.)
18. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:1992-2000.
19. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-9.